Al Sandrock, Voyager Therapeutics CEO
January 2, 2024 07:34 AM ESTUpdated 08:17 AM
Deals
Pharma
Cell/Gene Tx

No­var­tis dou­bles down on neu­ro­log­ic gene ther­a­py work with Voy­ager

Kyle LaHucik

Senior Reporter

No­var­tis has lined up two more neu­ro­log­ic dis­eases in its gene ther­a­py col­lab­o­ra­tion with Voy­ager Ther­a­peu­tics, this time pay­ing about …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

A service from the Financial Times